Company attributes
Other attributes
BlackThorn Therapeutics is a biopharmaceutical company developing neurobehavioural therapeutic treatments using artificial intelligence and clinical neuroscience that is headquartered in San Francisco, California and was founded in 2015 by Alex Tkachenko and Bill Martin. The company currently has two drugs in development (BTRX-225140 for treating mood and anxiety disorders, BTRX-323511 for treating autism) and one dedicated early discovery program for finding potential drug candidates.
On October 20, 2016 BlackThorn Therapeutics announced raising $40 million in series A funding from ARCH Venture Partners (lead investor), Mercury Fund, Johnson & Johnson Innovation, Altitude Life Science Ventures, and Alexandria Real Estate Equities. The company plans on using their series A funding to continue developing targeted and novel treatments for neurobehavioral disorders.
On January 5, 2017 BlackThorn Therapeutics announced raising $14 million in a series A funding round extension from GV and Biomatics Capital Partners. The series A extension funding brings BlackThorn Therapeutics series A funding round to a total of $54 million. The executive chairman of BlackThorn Therapeutics, Mark Corrigan, made the following comments about the company's series A extension:
We are delighted to welcome GV and Biomatics Capital to our investor team; both have approaches that are synergistic with our drug discovery and development platform. We appreciate the substantial interest in and support for our deep portfolio of best-in-class small molecules to treat patients with neurobehavioral disorders.
On June 20, 2017 BlackThorn Therapeutics announced raising $8 million in the form of grant funding from the National Institute of Neurological Disorders and Stroke for developing their Kappa Opiod Receptor (KOR) antagonist program.
On June 13, 2019 BlackThorn Therapeutics announced raising $76 million in series B funding from Vertex Ventures HC, Premier Partners, Polaris Partners, Mercury Fund, Johnson & Johnson Innovation, GV, Biomatics Capital Partners, Altitude Life Science Ventures, Alexandria Venture Investments, and ARCH Venture Partners. At the time of announcing their series B funding BlackThorn Therapeutics also announced adding Jane Tiller as the company's chief medical officer and Laura Hansen as the company's vice president of corporate affairs.
